The U.K.’s health-cost agency asked Bayer AG (BAYN) for more information on the cost and effectiveness of the Xarelto blood-thinning drug in the treatment and prevention of clots in deep veins.
The data presented by the German drugmaker failed to show Xarelto offered value for money to the state-run National Health Service, the National Institute for Health and Clinical Excellence said today in an e-mailed statement. Bayer, health- care professionals and members of the public may now comment on the draft guidance, the agency said.
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org